恩替卡韦治疗乙肝肝硬化合并肝源性糖尿病的临床疗效

Clinical efficacy of entecavir in treatment of hepatogenous diabetes

目的观察恩替卡韦治疗乙肝肝硬化合并肝源性糖尿病(HD)的临床疗效。方法 62例乙肝肝硬化合并肝源性糖尿病患者,按是否应用恩替卡韦抗病毒治疗分为治疗组和对照组各31例。观察48周的临床疗效。结果治疗48周后,治疗组病毒学应答率、肝功能、空腹血糖、糖化血红蛋白显著优于对照组。结论恩替卡韦治疗乙肝肝硬化合并肝源性糖尿病,能有效抑制HBV-DNA复制,ALT、AST、TBil、Alb均有明显改善,空腹血糖及糖化血红蛋白控制理想。

Objective To observe the clinical efficacy of entecavir in treatment ofhepatogenous diabetes （HD）. Methods 62 cases of patients with liver cirrhosis hepatogenic diabetes patients, according to whether the application of entecavir antiviral treatment were divided intotreatment group and control group with 31 cases in each. The clinical observation of 48 weeks. Results After 48 weeks treatment, the treatment group virologic response rate, liver function, fasting blood glucose, glycosylated hemoglobin was significantly better than the control group. Conclusion Entecavir treatment of hepatitis B liver cirrhosis complicated with hepatic diabetes, can effectively inhibit the replication of HBV-DNA, ALT, AST, TBil, Alb are significantly improved, fasting blood glucose and glycosylated hemoglobin control ideal.